Literature DB >> 25678187

Fibroblast growth factor receptor 1 as a target for the therapy of renal cell carcinoma.

Ilya Tsimafeyeu1, Gennady Bratslavsky.   

Abstract

Dysregulation of fibroblast growth factor (FGF) signaling in renal cell carcinoma is now well understood, and it is becoming increasingly likely that certain tumors become dependent on an activation of this pathway for their growth and survival. Dissecting the FGF/FGF receptor (FGFR) pathway offers the hope of developing new therapeutic approaches that selectively target the FGF/FGFR axis in patients whose tumors are known to harbor FGF/FGFR dysregulation. In this review, we summarize the existing data on the role of FGFR1 in the pathogenesis of renal cell carcinoma and discuss methodological issues for drug investigation in this setting.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25678187     DOI： 10.1159/000370118

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  6 in total

1.  Immunochemical expression of fibroblast growth factor and its receptors in primary tumor cells of renal cell carcinoma.

Authors:  Maria Volkova; Ilya Tsimafeyeu; Anna Olshanskaya; Yulia Khochenkova; Eliso Solomko; Saida Ashuba; Vsevolod Matveev; Dmitry Khochenkov
Journal:  Am J Clin Exp Urol       Date:  2021-02-15

2.  Carcinogenesis of renal cell carcinoma reflected in HLA ligands: A novel approach for synergistic peptide vaccination design.

Authors:  Martin G Klatt; Daniel J Kowalewski; Heiko Schuster; Moreno Di Marco; Jörg Hennenlotter; Arnulf Stenzl; Hans-Georg Rammensee; Stefan Stevanović
Journal:  Oncoimmunology       Date:  2016-06-30       Impact factor: 8.110

3.  FGFR2 overexpression predicts survival outcome in patients with metastatic papillary renal cell carcinoma.

Authors:  I Tsimafeyeu; A Khasanova; E Stepanova; M Gordiev; D Khochenkov; A Naumova; I Varlamov; A Snegovoy; L Demidov
Journal:  Clin Transl Oncol       Date:  2016-07-05       Impact factor: 3.405

4.  Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.

Authors:  Masahiro Matsuki; Yusuke Adachi; Yoichi Ozawa; Takayuki Kimura; Taisuke Hoshi; Kiyoshi Okamoto; Osamu Tohyama; Kaoru Mitsuhashi; Atsumi Yamaguchi; Junji Matsui; Yasuhiro Funahashi
Journal:  Cancer Sci       Date:  2017-04-20       Impact factor: 6.716

5.  Gene expression-based biomarkers for discriminating early and late stage of clear cell renal cancer.

Authors:  Sherry Bhalla; Kumardeep Chaudhary; Ritesh Kumar; Manika Sehgal; Harpreet Kaur; Suresh Sharma; Gajendra P S Raghava
Journal:  Sci Rep       Date:  2017-03-28       Impact factor: 4.379

6.  Expression of growth factors and their receptors in the primary renal cell carcinoma: new data and review.

Authors:  Maria Volkova; Ilya Tsimafeyeu; Anna Olshanskaya; Yulia Khochenkova; Elyso Solomko; Saida Ashuba; Dmitry Khochenkov; Vsevolod Matveev
Journal:  Cent European J Urol       Date:  2020-12-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.